Sage Therapeutics (NASDAQ:SAGE) Shares Cross Below 200-Day Moving Average - Time to Sell?

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.67 and traded as low as $5.72. Sage Therapeutics shares last traded at $5.85, with a volume of 722,997 shares.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SAGE shares. Royal Bank of Canada upgraded Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price target for the company in a research note on Thursday, November 21st. Scotiabank lowered their target price on shares of Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating on the stock in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research note on Wednesday, November 20th. HC Wainwright reiterated a "neutral" rating and issued a $14.00 price target on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Finally, Stifel Nicolaus cut their price objective on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a research report on Monday, December 16th. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $10.53.

Sage Therapeutics Price Performance

The stock has a market capitalization of $339.51 million, a PE ratio of -0.99 and a beta of 0.91. The firm has a fifty day moving average price of $5.58 and a two-hundred day moving average price of $7.66.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to analysts' expectations of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business's revenue for the quarter was up 337.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.81) EPS. On average, research analysts expect that Sage Therapeutics, Inc. will post -6.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several large investors have recently modified their holdings of SAGE. Quest Partners LLC lifted its position in Sage Therapeutics by 14.5% during the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company's stock valued at $128,000 after acquiring an additional 1,486 shares during the last quarter. AdvisorShares Investments LLC boosted its position in shares of Sage Therapeutics by 13.6% in the 2nd quarter. AdvisorShares Investments LLC now owns 16,030 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 1,918 shares in the last quarter. Headlands Technologies LLC grew its stake in Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 2,782 shares during the last quarter. Geode Capital Management LLC increased its position in Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after buying an additional 3,757 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 4,672 shares during the last quarter. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.